In addition, the pulmonary microbiota can upregulate CXCL9 in both cancer and myeloid cells, facilitating recruitment of CD8+ T cells into the tumor core and thereby improving the therapeutic efficacy of nivolumab [66]. This evidence concerns the gene CD8A and cancer.